Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05437588
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
10 Years - 24 Years
Healthy Volunteers
Accepted

Interventions

  • Genetic testing — GENETIC
    Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action

Study Details

This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.

Key Dates

Start date
Oct 1, 2022
Status verified
Jul 2025
Primary completion
Jun 29, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
240 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Other: MDD Participant
    Participants with MDD will return at six weeks for a second blood draw and assessments

Primary Outcome Measure

Clinical phenotype analysis [ Time Frame: 6 Weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Azka Aleezada
205-996-2723
UAB Huntsville Regional Medical CampusHuntsvilleAlabama35294
Jennifer Burns, MS
256-551-4677
Annalyse Alldredge, MA
256-551-4431
Yogesh Dwivedi, PhD (PRINCIPAL_INVESTIGATOR)
Richard C Shelton, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition

Related Studies